28 August 2018
Visiongain has launched a new pharma report Global Allergic Rhinitis Drugs Market 2018-2028: Oral Antihistamines, Intranasal Corticosteroids, Intranasal Antihistamines, Immunotherapy and Vaccines.
There is a high and rapidly increasing unmet clinical need in allergic rhinitis. The prevalence of allergic rhinitis is increasing, driven by factors such as climate change, industrialisation, and changes in our exposure to potential allergens in early life. The pattern of increasing prevalence has been observed worldwide. In addition, climate change could lead to seasonal allergic rhinitis symptoms being present for a much greater proportion of the year, due to grasses and trees producing pollen earlier and for longer periods.
The lead analyst of the report commented "Immunotherapy for allergic rhinitis is expected to significantly increase its share of the overall allergic rhinitis drugs market over the forecast period. The launch of sublingual immunotherapy tablets in the US and expansion in Asia-Pacific markets is expected to drive high growth in this segment of the allergic rhinitis drugs market.
Immunotherapy has advantages over intranasal drugs in being a therapy that may lead to long-term prevention of symptoms; the closest thing to a ‘cure’ in allergic rhinitis. The pipeline for immunotherapy is particularly strong. There have also been developments in sublingual immunotherapy (SLIT), which will expand the use of immunotherapy."
Leading companies featured in the report include ALK-Abello, GSK, Johnson & Johnson, Kyowo Hako Kirin, Merck & Co, Sanofi, Stallergenes Greer, UCB.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The technologies that will be in the greatest demand in this decade are those that provide flexibility and faster turnover times for pharma companies.
19 August 2019
Successful harnessing of the opportunities for growth in the ophthalmic pharmaceuticals market will depend upon the development of novel products with technologies that increase clinical effectiveness and development of products for previously-untreated ophthalmic conditions.
15 August 2019
The available reduced costs of outsourced manufacturing combined with access to the innovation power of CMOs are major drivers behind the decision to outsource manufacturing processes.
06 August 2019
The main appeal of 3D printed healthcare products to professionals is that each unit can be personalised to fit the recipient.